An Overview of Biochemical Aspects of DNA Vaccines

Manju Rawat, Deependra Singh, S. Saraf and Swarnlata Saraf
Institute of Pharmacy, Pt Ravishankar Shukla University,
Raipur (C.G.-) 492010, India

Abstract: DNA vaccines, also known as genetic or nucleic acid vaccines involve the transfection of cells in vivo by introducing DNA plasmid carrying an antigen-coding gene resulting in an immune response. The purpose of this article is to describe DNA vaccination, to discuss its importance, to review different technologies for improving expression of antigens and to illustrate how it could serve as an alternative for conventional vaccines. DNA vaccines have been prepared against bacterial and viral infections, tumors and allergies and were found to be efficacious in animal studies. These offer number of advantages in terms of ease of administration, manipulation, amplitude and duration of immune response, chemical and biological stabilities and simplicity of manufacture with cost consideration. But, this futuristic alternative needs an elaborate research on its efficacy and associated risks in order to establish the clinical utility of DNA vaccines. This article will explore various aspects of DNA vaccines including its associated advantages, disadvantages, mechanism of action, experimental models studied with a brief overview of second generation vaccines.

Key words: DNA vaccine, genetic vaccine, antigen processing, adjuvant, immunization, vaccination

INTRODUCTION

Vaccines are the biological preparations used to induce substantial immune response involving both humoral and cell mediated immunity to provide immune protection against most infective agents like viruses and bacteria. Vaccines usually include killed or attenuated form of the infectious agents, a modified product of infectious agents (toxoid) or a constituent of an infectious agent (such as the capsule) (Weiner and Kennedy, 1999). But, an urgent requirement is to develop vaccines that would be effective for intracellular parasites as well as safer to use. This has led to an increased surge of interest on the research relating to various aspects of vaccines leading to its widespread use.

DNA vaccines are new types of sub-unit vaccines whose delivery into living cells leads to expression of protein of interest in vivo and effective induction of both humoral and cellular immunity. Immunity conferred by DNA vaccines has been shown in many animal models of various diseases including HIV, tuberculosis and cancer (Lee et al., 2004; Ivory and Chadee, 2004; Bartek et al., 2004).

Origin of DNA vaccines dates back to early nineties. Mycobacterial ribosomal and ribonucleic acid preparations were the first nucleic acid preparations reported to be immunogenic (Youmans and Youmans, 1965), which was further supported by immunogenicity of pure RNA extracted from Salmonella typhimurium (Abdolmeor, 2001) But, later RNA was found to serve as adjuvant for the antigen contaminants in the Ribosome/RNA vaccines leading to its unsuitability (Eisenstein, 1975). In 1990, successful delivery and expression of plasmid DNA directly into mouse muscle in vivo was demonstrated (Wolf et al., 1990). The production of anti-human growth hormone (hGH) antibodies and successful induction of both antibody and CTL responses in mice injected with a plasmid DNA

Corresponding Author: Dr. (Mrs.) Swarnlata Saraf, Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur (C.G.-) 492010, India Tel: +91-771-2262832, +91-771-2262832

208
encoding hGH and influenza virus protein respectively created the surge of interest in this novel family of vaccines (Tang et al., 1992; Uliner et al., 1993).

Although a lot of work has been going on relating to development, characterization and clinical trials but major challenge is to demonstrate the clinical utility of DNA vaccines leading to its better and widespread application (Liu, 2003; Liu et al., 2006; Gurunathan et al., 2000; Garnory et al., 2003).

**DNA Vaccines**

DNA vaccine is a circular double stranded DNA molecule, referred to as a plasmid, containing genes encoding one or more proteins of a pathogen (Fig. 1). Plasmids are extra-chromosomal circular DNA molecules that are often present in multiple copies in bacterial cells. The plasmid contains a bacterial origin of replication by virtue of which it can replicate autonomously inside bacterial cells but not in eukaryotic cells. Such plasmids can be isolated from bacteria using simple and inexpensive protocols. Using recombinant DNA techniques, it is possible to insert a foreign gene into the plasmid molecule to generate a recombinant plasmid. When the gene is inserted downstream of DNA sequences referred to as promoter and enhancer elements to which eukaryotic RNA polymerase II and a host of proteins known as transcription factors bind, then the resultant plasmid is referred to as an eukaryotic expression plasmid.

When such plasmids are introduced into eukaryotic cells, the gene of interest is transcribed by the RNA polymerase II and other accessory proteins resulting in the synthesis of messenger RNA (mRNA) that is translated into the corresponding protein in the cytoplasm of host cells (Davis et al., 1996). In brief, the basic requirements for the backbone of a plasmid DNA vector are a eukaryotic promoter, a cloning site, a polyadenylation sequence, a selectable marker and a bacterial origin of replication (Gurunathan et al., 2000).

**Advantages**

- Plasmid DNA is found to be non-infectious, non-replicating and encodes only the antigen of interest as compared to live attenuated vaccines or viral carrier systems. 11)
- It induces both cell-mediated (Th1 and CTL) and humoral immunity responsible for improved performance of the vaccine (Butts et al., 1998).
- Induction of both immunity pathways effectively target virus-infected cells (Calarota et al., 2001).
- The cell-based immune system offers broad spectrum of action against heterologous strains of a pathogen with longer lasting immunity (Schodel et al., 1994).
- DNA vaccines induce in vivo expression of immunogens thus conserving the native conformation of epitopes (Schodel et al., 1994).
DNA vaccination can also be utilized for multiple gene expression by conserving an appropriate tertiary conformation for the induction of conformationally specific antibodies and cellular responses by including more than one immunogen gene, thus decreasing the vaccination frequency in children (Griffanti et al., 1998).

DNA vaccines offer the possibility of generating effective immune responses against diseases where other types of vaccines have failed such as malaria, AIDS and tuberculosis wherein a single antigen alone may not offer complete protection.

DNA vaccine plasmids can be constructed using simple recombinant DNA techniques and therefore it is possible to co-inoculate multiple plasmids encoding different antigens of same or different pathogens (Spier, 1996; Mahon, 2001).

Safer to use than live attenuated vaccines especially in immuno compromised hosts (Schodel et al., 1994; Lodmell et al., 1998).

DNA vaccines can be stored dry or in an aqueous solution at room temperature. DNA vaccines don’t require a cold-chain that constitutes nearly 80% of the cost of vaccinating individuals in developing nations.

DNA vaccines are stable, easy to freeze dry and reconstitute and can be manufactured inexpensively in large quantities in pure form (Spier, 1996; Lodmell et al., 1998).

Limitations

DNA vaccination approach can be used to induce immune responses only against the protein components of the pathogen and cannot substitute for polysaccharide based subunit vaccine for e.g., diseases caused by pathogens such as Pneumococcus.

Although, DNA vaccines has been demonstrated to induce protective immune response but the mechanism of DNA vaccine action is still not completely understood. The potential risks of using plasmid DNA encoding cytokines or co-stimulatory molecule in the host is not yet known.

DNA vaccines might be associated with the risk of insertional mutagenesis as the plasmid DNA integrates into the genome randomly. If plasmid DNA integrates into the host genome it may either activate oncogenes or suppress tumor genes, which may lead to a malignant transformation.

On intradermal administration of DNA vaccines, the transfected epidermal cells are lost within 10-14 days because of the normal sloughing of keratinized skin tissue whereas on intramuscular administration, the transfected muscle cells remain non-dividing and random insertion is more likely to occur in replicating cells in which DNA is actively being synthesized (Simmonds et al., 1997; Robertson, 1994).

Another major concern is the induction of anti-DNA antibodies by plasmid DNA. Antibodies to DNA can cause disease and are associated with Systemic Lupus Erythematosus (SLE) (Robertson, 1994).

The minute amount of antigens produced by transfected cells may induce a state of tolerance of plasmid encoded antigen which appears to persist for long periods of time but, unresponsiveness, rather than protective immunity might result (Simmonds, 1997; Lopez-Macias et al., 1995).

Potential harmful effects of bacterial ISS (CpG motifs) must also be considered. Schwartz et al. (1997) and Pisetsky (1997) reported that CpG motifs in bacterial DNA caused inflammation in lower respiratory tract.

Mechanism of Action of DNA Vaccines

General Uptake Mechanism

DNA vaccines are prepared by recombinant DNA technology whereby genes encoding antigenic proteins of a pathogen are inserted into the vector plasmid (Mor and Eliza, 2001; Spier, 1996).
plasmid DNA enters the cell and then into nucleus where it undergoes transcription and translation to express encoded gene product in cytoplasm, which leads to generation of humoral and cell-mediated immune response (Fig. 2).

Antigen presentation essentially involves proteolytic degradation of the foreign proteins inside the eukaryotic cells and association of the proteolytic fragments with two different types of Major Histocompatibility Complex (MHC) proteins referred to as class I and class II MHC proteins. Class I molecules present protein fragments to cytotoxic T-cells whereas Class II molecules present protein fragments to T-helper cells (Fig. 3).

In case of DNA vaccination, since the pathogenic proteins are synthesized inside the host cells, both humoral and cell-mediated immune responses can be induced. Activation of branches of the immune system requires cytokines produced by T_{H} cells. To ensure carefully regulated activation of T_{H} cells, they can recognize only antigen that is displayed together with class MHC II molecules on the surface of Antigen Presenting Cells (APCs). APCs are specialized cells which express class II MHC molecules on their membranes and deliver a co-stimulatory signal that is necessary for T_{H} cell activation. Antigen Processing/Presenting Cells (APC) degrade a protein antigen into smaller peptides and present the peptide to T-lymphocytes, which eventually are activated. Three cell types are classified as professional APCs: dendritic cells, macrophages and B-lymphocytes. Several other cell types, classified as non-professional APCs: Fibroblasts, thyroid epithelial cells, Gial cells and vascular endothelial cells can be induced to express class II MHC molecules or a co-stimulatory signal.
Fig. 3: Cytosolic and endocytic pathway for antigen processing
(Endogenous antigens are processed in the cytosolic pathway and exogenous antigens are processed in the endocytic pathway)

A number of studies have been performed to determine the ability of APC to take up plasmid DNA, process it and activate both humoral and cell-mediated branches of immune system. Studies performed by Wolff et al. (1990) and Ulmer et al. (1993 and 1996) suggested that myocytes behaved as APCs on administration of plasmid DNA by intramuscular route but it does not share the later property of APCs. Agadjanyan et al. (1999) showed that muscle cells could induce antigen-specific CTL responses only when the mice were vaccinated with plasmid DNA possessing an antigen and B7 (co-stimulatory molecule) reporter genes. Keratinocytes and/or Langerhans cells might be the APC that are transfected (Klinman et al., 1997).

Later reports indicated that the bone marrow derived dendritic cell is the principal APC involved in plasmid DNA immunization. The plasmid DNA could either transfec somatic cells (myocytes, keratinocytes) or bone marrow derived dendritic cells. When the plasmid DNA is taken up by myocytes or keratinocytes, product encoded by reporter gene is then transferred to dendritic cells by cross priming. Findings by Ulmer et al. (1996) favored this processing mechanism by inducing both antibody and CTL responses to influenza nucleoprotein in mice by transplanting transfected myoblasts. Furthermore isolation of plasmid DNA from lymph node derived and skin derived dendritic cells after intra-muscular or intra-dermal administration, respectively favored direct transfection of bone marrow derived dendritic cells (Casares et al., 1997).

**Mechanism of Antigen Processing/presentation**

Major Histocompatibility Complex (MHC) class I and class II molecules play major role in presenting a processed antigen to T-lymphocytes. MHC class I molecules are expressed on the surface of practically all nucleated cells (York and Rock, 1996). They consist of two polypeptide chains—an alpha chain and β-2 microglobulin.

The immune system uses two different pathways to eliminate intracellular and extracellular antigens. Endogenous antigens are processed in the cytosolic pathway and presented on the membrane.
with class I MHC molecules; exogenous antigens are processed in the endocytic pathway and presented on the membrane with class II MHC molecules.

Intracellular proteins such as viral, protozoal, bacterial and tumor proteins are degraded into short peptides by a cytosolic proteolytic system present in all cells. Those proteins targeted for proteolysis often have a small protein called ubiquitin, attached to them. A multi-functional protease complex called a proteasome can degrade ubiquitin-protein conjugates. The proteasomes involved in antigen processing include two sub-units encoded within the MHC gene cluster, LMP2 and LMP7 and a third non-MHC protein LMP10. Transporter proteins (TAP1/TAP2) translocate peptides generated in the cytosol by the proteasome into the Rough Endoplasmic RETICULUM (RER) by a process that requires the hydrolysis of ATP. TAP is optimized to transport peptides that will interact with class I MHC molecules. Molecular chaperones facilitate the folding of poly-peptides in order to form stable class I MHC molecular complex that can exit the RER. The tri-molecular complex (alpha chain, beta-2-microglobulin and peptide) is then transported to the cell outer membrane and presented to the CD8+ CTL. These lymphocytes become fully activated following second signals that include cytokine-receptor (such as IL-2 and IL2R) and co-stimulatory molecule-receptor (such as B7 and CD28) interactions. The activated CD8+ CTL produce perforins that polymerize in the cell membrane of the target cell (e.g., cell infected with the virus) causing its death (York and Rook, 1996).

MHC class II molecules are expressed mainly on APC where they present processed antigenic peptides to T₈ cells (Mach et al., 1996). MHC class II molecules contain two different polypeptide chains, a 33 kDa alpha chain and a 28-kDa Beta chain, which associate by non-covalent interactions. Each chain in a class II molecule contains two external domains-ε, and ε, domains in one chain and β₂ domains in the other, a transmembrane region and an intracytoplasmic region.

APC internalize exogenous antigens by phagocytosis, endocytosis or both (Watts, 1997; Castellino et al., 1997). Once an antigen is internalized it is degraded into peptides within compartments of the endocytic-processing pathway. Internalized antigen move from early to late endosomes and finally to lysosomes, encountering hydrolytic enzymes and a lower pH in each environment. When class II molecules are synthesized within the RER, three pairs of class II α, β chains associate with the pre-assembled trimer of a protein called invariant chain. This trimeric protein interacts with the peptide-binding cleft of the class II molecules, preventing any endogenously derived protein from binding to the cleft while the class II molecule is within the RER. As the proteolytic activity increases in each successive compartment, invariant chain is gradually degraded. However, a short fragment of the invariant chain termed CLIP (for class II associated invariant chain peptide) remains bound to the class II molecule after the invariant chain has been cleaved within the endosomal compartment. A non-classical class II MHC molecule called HLA-DM is required to catalyze the exchange of CLIP with antigenic peptides. Complex formed is then transported to the plasma membrane and is presented to CD4+ T-lymphocytes (T-helpers). These lymphocytes become activated following second signals that include cytokine-receptor and co-stimulatory molecule-receptor interactions. There are at least 2 sub-populations of T-helpers (Th), Th1 and Th2. Activation of either of the two sub-populations predominates depending on the cytokines produced (interleukin (IL)-12 favors the Th1 response and IL-4 favors a Th2 response), the co-stimulatory molecules involved (B7.1-CD28 interaction favors a Th1 response; B7.2-CD28 interaction favors a Th2 response) and the route of entry of the antigen (Romagnani, 1997). Activated Th1 mainly produces IL-2 and gamma-interferon whereas activated Th2 mainly produces IL-4, IL-5, IL-6, IL-10 and IL-13. Cytokines produced in a Th1 response mediate Delayed Type Hypersensitivity, are involved in the activation of CTL, macrophages and NK-cells and help B-lymphocytes to eventually produce IgG2a and IgG3 class antibodies. On the other hand, cytokines produced in a Th2 response promote eosinophil proliferation and production of IgG1 and IgE class antibodies by B-lymphocytes. Maximized Th1 and CTL response are needed for protection against intracellular parasites and tumors.
Some reports indicated that exogenous proteins may be processed, complexed to MHC class I molecules and presented to CTL (Bevan, 1987; Carbone and Bevan, 1990; Kovacs-Novak et al., 1993; Kovacs-Novak and Rock, 1995; Shen et al., 1997; Reis et al., 1995; Norbury et al., 1995). By a yet not well-defined mechanism called cross priming, the antigen may be either shuttled directly into the cytosol of the APC, or it may be engulfed by phagocytosis and leaks out of the endosome/lysosome compartment into the cytosol.

DNA Immunization

Route of Administration

Several routes of plasmid DNA inoculation have been studied in animal models. These include intramuscular, sub-cutaneous, intra-peritoneal, intra-dermal, intra-venous, oral, rectal, intra-bursal, intra-orbital, intra-tracheal, intra-nasal and vaginal routes (Simmonds et al., 1997; Mor et al., 1995).

In the case of a plasmid DNA vaccine for a tumor, it can be injected into the tumor site (Fuller et al., 1997). The most common routes of administration are by injecting the plasmid DNA dissolved in saline intra-muscularly or intra-dermally using a hypodermic needle or by bombarding plasmid DNA coated onto colloidal gold microparticles in the dermis or muscle using a gene gun.

Effective Dose

The dose used in mice depends on the method of administration. Usually an immune response is generated when 10-100 μg of plasmid DNA is injected and 0.1-1 μg when it is administered with a gene gun (Fynan et al., 1993). Immune response is increased when 1 or 2 boosters are given (Fuller and Haynes, 1994; Fuller et al., 1997; Mustafa et al., 1997; Richmond et al., 1997; Lu et al., 1997). However, time intervals between boosters appear to be critical. In two studies, it has been shown that an increase in the time interval between immunizing doses resulted in an increased immune response (Fuller et al., 1997; Leitner et al., 1997).

Duration of Immune Response

DNA vaccines generally produce long lasting immunity. Akbari et al. (1999) reported that antigen-specific CD4+ T-lymphocytes remained elevated for up to 10 months following immunization with a DNA vaccine and Gurunathan et al. (2000) reported long-term antigen-specific Th1 activity in mice immunized with a DNA vaccine containing a gene that coded for a Leishmania antigen. CTL responses and antibody levels were observed for up to 17 months in mice immunized with a DNA vaccine containing a reporter gene coding for an influenza virus protein and a DNA vaccine containing a reporter gene coding for hepatitis B protein, respectively (Raz et al., 1994; Davis et al., 1995).

The observed prolonged duration of the immune response has been reported to be due to the persistence of the antigen produced in the host. Wolff et al. (1992) detected antigen in muscle for up to more than 1 year and influenza virus nucleoprotein (Raz et al., 1994) in the dermis for one month, post plasmid DNA inoculation.

Strength of Immune Response

An optimum immunization regimen using the DNA vaccines involves priming the host and subsequently boosting with the antigen. Letvin et al. (1997) primed rhesus monkeys with plasmid DNA containing HIV env gene. Subsequent boosters were done using a combination of the plasmid DNA and HIV env protein. Strong CTL and neutralizing antibody activity were observed.

Experimental Models of DNA Vaccines

DNA vaccines have been studied in various animal models (Table 1). DNA vaccination strategy resembles virus infection, as the genes transferred by the plasmids require the host cellular machinery to be expressed and thus effective against viral infections.
Table 1: Models of DNA vaccines

<table>
<thead>
<tr>
<th>Infections agent</th>
<th>Animal model</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B virus</td>
<td>Mouse</td>
<td>Chow et al. (1997)</td>
</tr>
<tr>
<td></td>
<td>Rabbit</td>
<td>Prince et al. (1997)</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>Davis et al. (1996)</td>
</tr>
<tr>
<td></td>
<td>Chimpanzee</td>
<td>Donnelly et al. (1996)</td>
</tr>
<tr>
<td>Rabies virus</td>
<td>Macaca fascicularis</td>
<td>Lohmell et al. (1998)</td>
</tr>
<tr>
<td></td>
<td>(Cynomolgus)monkeys</td>
<td>Xiang et al. (1994 and 1995)</td>
</tr>
<tr>
<td>Sinian/Human immunodeficiency virus</td>
<td>Macaques</td>
<td>Singh et al. (2005), Hegde et al. (2005)</td>
</tr>
<tr>
<td>Hepatitis C virus</td>
<td>Mouse</td>
<td>Xiang et al. (1995)</td>
</tr>
<tr>
<td>Herpes simplex virus</td>
<td>Mouse</td>
<td>Manickan et al. (1995)</td>
</tr>
<tr>
<td>Human immunodeficiency virus-1</td>
<td>Mouse</td>
<td>Lu et al. (1997), Wang et al. (1995)</td>
</tr>
<tr>
<td>Influenza virus</td>
<td>Chicken</td>
<td>Ulmer et al. (1993)</td>
</tr>
<tr>
<td></td>
<td>Ferrets</td>
<td>Taubes (1997),</td>
</tr>
<tr>
<td></td>
<td>Nonhuman primates</td>
<td>Mac Greger et al. (2000)</td>
</tr>
<tr>
<td>Lymphocytic chorion-meningitis virus</td>
<td>Mouse</td>
<td>Yokoyama et al. (1995)</td>
</tr>
<tr>
<td>Papillomavirus</td>
<td>Rabbit</td>
<td>Donnelly et al. (1996)</td>
</tr>
<tr>
<td>Bacterial diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mycobacterium tuberculosis</td>
<td>Mouse</td>
<td>Orme et al. (2001), Lowrie et al. (1994)</td>
</tr>
<tr>
<td>Protozoal diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasmodium falciparum</td>
<td>Aotus monkey</td>
<td>Graminski et al. (1997)</td>
</tr>
<tr>
<td>Plasmodium yoelii</td>
<td>Mouse</td>
<td>Hoffman et al. (1994)</td>
</tr>
<tr>
<td>Mycoplasma pneumonia</td>
<td>Mouse</td>
<td>Barry et al. (1995)</td>
</tr>
<tr>
<td>Leishmania major</td>
<td>Mouse</td>
<td>Xu and Leit (1995)</td>
</tr>
</tbody>
</table>

However, genes from other microorganisms have also been used with success. Immunization response for HBV surface antigen in terms of the humoral response in mice mimics, to a certain extent that observed during infection in humans (Boyer et al., 2000). T-cell proliferation and cytokine secretion have been studied in several models and the cytokine profile indicates a Th1 type response characterized by the secretion of interleukin-2 and α-interferon.

The immune response can be remarked long-lasting; however the duration of the immune response does not appear to have any deleterious effects on the animals because they are protected against challenge long after immunization (Xiang et al., 1995). One human trial used plasmid vector expressing HIV-1 genes delivered to HIV-seropositive persons by intra-muscular injection. This protocol used Marcaine to facilitate DNA uptake, although the mechanism of this effect has not been clearly delineated (Wang et al., 1993). A number of clinical trials have also been initiated since plasmid DNA is now considered an innocuous substance compared with other genetic vectors used in therapy.

Clinical Trials

Vaccines have been mostly studied for infectious diseases and so is the case with DNA vaccines. Immune responses induced by plasmid DNA vaccines depend on means of administration and/or coadministration of an immunomodulator gene. Clinical trials of DNA vaccines are under way for various diseases including cancer, influenza, Hepatitis B, HIV, malaria (Taubes, 1997). But because of the difference between humans and animals in terms of morphology and anatomy further trials are required to be done on humans to confirm its efficacy.

Phase I clinical trials were initiated to evaluate the safety and immunogenicity of HIV-1 env/rev DNA constructs in infected and uninfected persons (Mac Greger et al., 1998). The uninfected persons who received the highest dose of DNA vaccine had antigen specific lymphoproliferative responses and antigen specific production of interferon γ and β-chemokines, but these responses were weak and did not persist (Boyer et al., 2000). In the infected persons, an HIV-1 env/rev DNA vaccine construct boosted the env-specific antibodies; however no consistent effect was observed on cellular
responses to HIV. Another phase I clinical trial evaluated HIV regulatory genes, such as rev, nef and tat. Immunization of infected persons with these genes enhanced cellular responses but produced no consistent changes in lymphocytes subsets or viral load (Mac Greager et al., 1998, 2000; Calarota et al., 1998). The DNA vaccines were well tolerated in doses from 20 µg up to 2500 µg; no significant local or systemic reactions were observed and no participant dropped out of the study (Mac Greager et al., 2000; Le et al., 2000).

In the study by Wang et al. (1998) involving phase I clinical trial of malaria DNA vaccines, 20 subjects were vaccinated with plasmid DNA encoding P. falciparum circumsporozoite protein (Reynolds et al., 1981). After immunization 11 of the 20 subjects showed malaria specific, classic cytotoxic T-cells (cytolytic activity restricted by HLA class I antigens) in their blood. Immunization with either a 500 µg dose or a 2500 µg dose of DNA induced a better cellular response than immunization with a 20 µg dose or 100 µg dose of DNA. These results indicated the ability of DNA vaccines to induce specific cellular immunity in humans. But, the protective effects of vaccine against malaria are still not confirmed by above findings. A phase I trial of an experimental HIV vaccine that includes an HIV A subtype gag gene and more than 40 bits of DNA encoding regions of HIV proteins is in progress in Kenya. This is the first component of a prime boost vaccination strategy and will be followed by a second vaccine using modified vaccinia virus as a vector (Reynolds et al., 1981). Another phase I clinical trial was recently started in infected and uninfected person to directly compare vaccines in which the gene is delivered as naked DNA or by attenuated adenovirus (Cohen, 2001).

A DNA vaccine against Hepatitis B virus was evaluated for safety and immunogenicity in a phase I clinical trial involving naive healthy volunteers. A gene gun was used to propel the DNA into the skin. The hepatitis B DNA vaccine was found to be safe well tolerated and immunogenic (Roy et al., 2000).

Current phase I and II trials are studying DNA vaccines as potential immunotherapies for various cancers, including colon cancer, human follicular lymphoma and cutaneous T-cell lymphoma.

**Comparison of DNA Vaccine and Conventional Vaccine**

- DNA vaccines induce a full spectrum of immune responses in transfected cells. These exhibit freedom from inherent risks of attenuated vaccines reverting to the virulent form.
- DNA vaccines, unlike viral recombinant, can be used repeatedly for different immunogens.
- Conventional vaccines like inactivated or protein vaccines require addition of adjuvants for improved immune response leading to induction of local inflammatory reaction whereas DNA vaccines provide their own adjuvant through unmethylated Cytosine linked to Guanine (CpG) sequences present in the bacterial part of the vector (Klinman et al., 1999).
- Inactivated vaccines and proteins commonly induce Th2 responses, such as in the case of some infection with respiratory syncitial virus might actually exacerbate disease upon infections whereas DNA vaccines upon intramuscular immunization induce Th1 responses.
- Peptide vaccines induce monospecific B or T cell responses, particularly useful for treatment of cancer, where known point mutation of a self-protein, such as p53 creates a T-cell epitope. Peptides require the addition of adjuvants, especially if the induction of CD8+ T cells is required. Furthermore, peptides are in general poorly immunogenic, which in part reflects their short serum half-life. DNA vaccines carrying mini genes for expression of single epitopes can readily be constructed to replace peptide vaccines. Many of the traditional vaccines fall to induce immune responses in neonates as most traditional vaccines are impaired in the presence of maternally transferred antibodies, whereas DNA vaccines readily stimulate T and B cell responses and when given to neonates are only marginally affected by the mother’s immune status (Table 2).
Table 2: DNA vaccines in comparison with other conventional vaccines

<table>
<thead>
<tr>
<th>Properties</th>
<th>Attenuated pathogens</th>
<th>Inactivated pathogen</th>
<th>Live recombinant vector</th>
<th>Protein vaccine</th>
<th>Peptide vaccine</th>
<th>DNA vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibody response</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Antibody rise</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>CTL induction</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>Variable</td>
<td>+</td>
</tr>
<tr>
<td>T-helper induction</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Complete antigen repertoire</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Possible</td>
</tr>
<tr>
<td>Immune response to the vaccine carrier</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Duration of response</td>
<td>Long</td>
<td>Short</td>
<td>Long</td>
<td>Short</td>
<td>Short</td>
<td>Long</td>
</tr>
<tr>
<td>Number of required vaccine doses</td>
<td>One</td>
<td>Multiple</td>
<td>Multiple</td>
<td>Multiple</td>
<td>One or more</td>
<td>Probable</td>
</tr>
<tr>
<td>Safety (especially for pregnant and</td>
<td>-</td>
<td>++</td>
<td>-</td>
<td>++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>immunosuppressed individuals)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk of reversion</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Impaired efficacy in the presence of maternal</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>antibodies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Cost: Variable, Difficult, Expensive, Difficult, Difficult, Easy

Second Generation Vaccines

As simple plasmids, DNA vaccines effectively induce immune responses and protection in various animal models of disease, but they have induced only modest immune responses in clinical trials. So, the need for even more effective vaccines has led to yet another class of second-generation vaccines. Various strategies have been employed to improve expression of antigens. Strategies may include the incorporation of immunostimulatory sequences in the backbone of the plasmids, co-expression of stimulatory molecules, utilization of localization/secretory signals and utilization of the appropriate delivery system. Optimization of transgene expression is an important consideration. Various strategies involve the modification of regulatory elements such as promoter/enhancers or other transcriptional elements (Chapman et al., 1991; Kevissa et al., 2000). Another element which can be effectively modified includes kozak sequences which are sequences flanking the AUG initiator codon within mRNA influencing recognition by eukaryotic ribosomes. As a result of studying the conditions required for optimal translational efficiency of expressed mammalian genes, the 'Kozak' consensus sequence has been shown to be important (Kozak, 1987 and 1997). Codon bias is observed in all species and the use of selective codons in genes often correlates with gene expression efficiency (Zarzinski et al., 1995). Nagata et al. (1999) studied the effect of codon optimization for mammalian cells of Cytotoxic T-Lymphocyte (CTL) epitopes derived from the intracellular bacterium, Listeria monocytogenes and the parasite Plasmodium yoelii and reported that the codon optimization level of genes correlated well with translational efficiency in mammalian cells.

The greatest deviation from random codon usage in an organism occurs in the highly expressed genes as a result of selection for codons that maximize translational efficiency (Grosjean and Fliers, 1982). A number of other studies have reported that increased immune responses may be obtained by DNA vaccination with a transgene sequence with optimised codon usage (Demic et al., 2001). The backbone of a DNA vaccine vector could be further modified to enhance immunogenicity via the manipulation of the DNA to include certain sequences, so that the DNA itself will have an adjuvantising effect. DNA vaccine vectors contain may CpG motifs (consisting of unmethylated CpG dimucleotides flanked by two 5' purines and two 3' pyrimidines) that, overall, induce a Th1-like pattern of cytokine production (Klinman et al., 1997) and are thought to account for strong CTL responses frequently seen following DNA vaccination (Krieg et al., 1998). It is possible to augment responses to DNA vaccine vectors by incorporating CpG motifs into the DNA backbone of the plasmid (Weerathna et al., 2001). Alternatively, immune responses may be modulated or enhanced by the co-expression of stimulatory molecules or cytokinas (Haddad et al., 2000) or through the use of localisation or secretory signals (Boyle et al., 1997; Lewis et al., 1997, Rice et al., 1999).
Future Prospects

Animal model studies of DNA vaccines have demonstrated success in generating protective immunity not only against viral infections but also against bacterial infection and cancer. But, the major thrust area is the establishment of its safety by means of pre-clinical and then clinical studies, while at the same time considering the benefit of a protective vaccination. As compared to other recombinant protein pharmaceuticals DNA vaccines involve the direct delivery of plasmid DNA itself rather than the protein produced by it as the final product. The potential benefits of DNA vaccination clearly outweigh the associated risks and expeditious approval of DNA vaccine clinical trials will provide important safety information for other applications.

Although an extensive DNA vaccine research has been underway, some researchers are already exploring the idea of using the genome sequence data of several pathogenic microbes to develop genomic vaccines. This approach, also known as expression library immunization, envisages immunization of animals with groups of plasmids encoding 100-1000 genes of a pathogen.

Barry et al. (1995) prepared very small amounts of DNA required with the particle bombardment method. Since a single nanogram of DNA coated on the gold particles induced an immune response, 1 µg can potentially induce 1000 different genes. On this basis a library of gene fragments was prepared from Mycoplasma pulmonis by cloning the genomic DNA into a plasmid expression vector. So, protection against M. pulmonis has been achieved after immunization with different expression libraries (Eisenbraut et al., 1993).

In spite of such an extensive and elaborate research pertaining to DNA vaccine development there are certain key areas such as amount of plasmid DNA to be administered, delivery specification to appropriate antigen presenting cells, antigen expression by DNA vaccines, number of boosters to be given and time interval between boosters need to be optimized. Therefore the major challenge in this field of research is to establish the clinical utility of DNA vaccines for the ultimate benefit of mankind.

REFERENCES


Kozak, M., 1997. Recognition of AUG and alternative initiator codons is augmented by G in position +4 but is not generally affected by the nucleotides in positions +5 and +6. EMBO J., 16: 2482-2492.


